BioThrax receives market authorization In India, Emergent BioSolutions says

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced Feb. 12, 2009, that it can market and sell BioThrax in India now that the Drugs Controller General of India has issued a registration certificate for the anthrax vaccine.

Emergent BioSolutions has signed a marketing agreement with Biological E. Limited to market BioThrax in India.

In 2008 the government of India provided guidance with respect to the management of biological disasters and stated that there is a need to have a supply of readily available anthrax vaccines to be administered rapidly in the event of an outbreak. The Indian National Disaster Management Authority also stated that all first responders would be vaccinated in an impending disaster.

BioThrax is the only vaccine for the prevention of anthrax infection licensed by the U.S. Food and Drug Administration.

Emergent BioSolutions Inc., formed in 2004, is dedicated to the research, development and manufacture of products that harness the immune system to treat and prevent disease. These include vaccines and related products for prophylactic and therapeutic use against common infectious diseases and biological weapons of mass destruction.